Histopathologic Features in Relation to Pretreatment Tumor Growth in Patients with Glioblastoma.
暂无分享,去创建一个
Ole Solheim | Øyvind Salvesen | Anne Line Stensjøen | Erik Magnus Berntsen | S. Torp | Ø. Salvesen | O. Solheim | E. M. Berntsen | I. Nordrum | Sverre Helge Torp | Vilde Elisabeth Mikkelsen | Ivar Skjåk Nordrum | V. E. Mikkelsen
[1] Gargi Chakraborty,et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. , 2009, Cancer research.
[2] Paul Thompson,et al. Mapping tumor growth rates in patients with malignant gliomas: A test of two algorithms , 2000, NeuroImage.
[3] K. Tsuboi,et al. Regrowth patterns of supratentorial gliomas: estimation from computed tomographic scans. , 1986, Neurosurgery.
[4] Ole Solheim,et al. Growth dynamics of untreated glioblastomas in vivo. , 2015, Neuro-oncology.
[5] Daniel J Brat,et al. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma , 2004, Laboratory Investigation.
[6] G. Semenza,et al. Expression of hypoxia‐inducible factor 1α in brain tumors , 2000 .
[7] Jiri Zavadil,et al. Knock down of HIF-1α in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres , 2010, Molecular Cancer.
[8] Alexander R. Pico,et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.
[9] S. Torp,et al. The Histopathological Spectrum of Primary Human Glioblastomas with Relations to Tumour Biology , 2012 .
[10] B A Kall,et al. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. , 1987, Journal of neurosurgery.
[11] B. Kálmán,et al. Molecular Heterogeneity of Glioblastoma and its Clinical Relevance , 2014, Pathology & Oncology Research.
[12] D. Scheie,et al. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme , 2010, Acta neurologica Scandinavica.
[13] J. Murray,et al. Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion , 2003, Journal of the Neurological Sciences.
[14] Rolf Bjerkvig,et al. In vivo models of primary brain tumors: pitfalls and perspectives , 2012, Neuro-oncology.
[15] D. Brat,et al. Diagnosis of malignant glioma: role of neuropathology , 2008, Journal of Neuro-Oncology.
[16] B. Scheithauer,et al. Cellular proliferation in pilocytic and diffuse astrocytomas. , 1999, Journal of neuropathology and experimental neurology.
[17] K. Aldape,et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[18] T. Taxt,et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma , 2011, Proceedings of the National Academy of Sciences.
[19] W Ellis,et al. The influence of volumetric tumor doubling time, DNA ploidy, and histologic grade on the survival of patients with intracranial astrocytomas. , 1995, AJNR. American journal of neuroradiology.
[20] Z L Gokaslan,et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.
[21] D. Ross,et al. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. , 1997, Journal of neuropathology and experimental neurology.
[22] Laird Ak. DYNAMICS OF TUMOR GROWTH. , 1964 .
[23] S. Raab,et al. Interobserver variability associated with the MIB‐1 labeling index , 2001, Cancer.
[24] G. Reifenberger,et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Wardlaw,et al. A pilot study of brain tumour growth between radiotherapy planning and delivery. , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).
[26] D. Louis. WHO classification of tumours of the central nervous system , 2007 .
[27] T. Cloughesy,et al. Contrast‐enhancing tumor growth dynamics of preoperative, treatment‐naive human glioblastoma , 2016, Cancer.
[28] Albert Lai,et al. Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. , 2009, Cancer research.
[29] H. Wakimoto,et al. Prognostic significance of Ki‐67 labeling indices obtained using MIB‐1 monoclonal antibody in patients with supratentorial astrocytomas , 1996, Cancer.
[30] G. Reifenberger,et al. Molecular neuro-oncology in clinical practice: a new horizon. , 2013, The Lancet. Oncology.
[31] A. Beckett,et al. AKUFO AND IBARAPA. , 1965, Lancet.
[32] F. Gaillard,et al. MRI Grading versus Histology: Predicting Survival of World Health Organization Grade II–IV Astrocytomas , 2015, American Journal of Neuroradiology.
[33] P. Wen,et al. Response Assessment in Neuro-Oncology , 2011, Current oncology reports.
[34] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[35] R. Bourgon,et al. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] B. Su,et al. Tissue factor expression and angiogenesis in human glioma. , 2002, Clinical biochemistry.
[37] Anne Line Stensjøen,et al. Does Pretreatment Tumor Growth Hold Prognostic Information for Patients with Glioblastoma? , 2017, World neurosurgery.
[38] D. Brat,et al. RESEARCH ARTICLE: Intravascular Thrombosis in Central Nervous System Malignancies: A Potential Role in Astrocytoma Progression to Glioblastoma , 2007, Brain pathology.
[39] M. J. van den Bent,et al. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? , 2011, The Lancet. Oncology.
[40] T. Bathen,et al. Differentiating diffuse World Health Organization grade II and IV astrocytomas with ex vivo magnetic resonance spectroscopy. , 2013, Neurosurgery.
[41] D. Altman,et al. STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.
[42] Akio Asai,et al. Morphological and flow cytometric analysis of cell infiltration in glioblastoma: a comparison of autopsy brain and neuroimaging , 2010, Brain Tumor Pathology.
[43] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] D. Zagzag,et al. Angiogenesis in Gliomas: Biology and Molecular Pathophysiology , 2005, Brain pathology.
[45] David N Louis,et al. Molecular pathology of malignant gliomas. , 2006, Annual review of pathology.
[46] R. Prayson,et al. Role of MIB1 in Predicting Survival in Patients with Glioblastomas , 2005, Journal of Neuro-Oncology.
[47] R. Prayson. Cell Proliferation and Tumors of the Central Nervous System Part 1: Evaluation of Mitotic Activity , 2002, Journal of neuropathology and experimental neurology.
[48] T. Kuwabara,et al. Estimation of rate of growth of malignant brain tumors by computed tomography scanning. , 1983, Surgical neurology.
[49] J. Kuratsu,et al. Expression of tissue factor correlates with grade of malignancy in human glioma , 1996, Cancer.
[50] Daniel J Brat,et al. 'Pseudopalisading' Necrosis in Glioblastoma: A Familiar Morphologic Feature That Links Vascular Pathology, Hypoxia, and Angiogenesis , 2006, Journal of neuropathology and experimental neurology.